Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

Supplemental materials for: Johnson et al

Files in this Data Supplement:

• Table S7 (PDF, 44.1 KB) -
  Part 1: SNPs associated to a permutated p < 0.05 with thalidomide VTE, showing the most significant model - Hovon-50 and ECOG EA100. Part 2: SNPs associated to a permutated p < 0.05 with thalidomide VTE, showing most significant model - Hovon-50 and ECOG EA100.
  
  
• Table S8. Non-synonymous SNPs associated to a permutated p < 0.05 with thalidomide VTE, tested by Fisher�s allelic test with in-silico functional predictions � Myeloma IX (PDF, 17.2 KB)
  
  
• Table S9. Pathways enrichment of genes associated with thalidomide VTE in Myeloma IX samples (PDF, 17.3 KB)
  
  
• Table S10. SNP × SNP interactions associated with thalidomide VTE in Myeloma IX samples (PDF, 16.1 KB)
  
  
• Table S11. Meta-analysis of associated SNPs with thalidomide VTE across three clinical trial sample sets (PDF, 28.4 KB)
  
  
• Table S12. Recursive Partitioning: dataset sample and trial distributions (PDF, 11.6 KB)
  
  
• Table S13. Classification of samples using predictive tree (PDF, 11.3 KB)